ENDACEA is developing its lead compound A1 adenosine receptor antagonist, L-97-1, as an intravenous treatment for sepsis and acute renal failure.
ENDACEA is developing a mutant plasmid cDNA for the A1 adenosine receptor for a cancer treatment. When this treatment was administered as an intratumor injection in mice with prostate cancer, the tumor volume was reduced by 84 percent.
ENDACEA’s lead compound A1 adenosine receptor (AR) antagonist, L-97-1, is a “best in class” A1 AR antagonist. This compound has a high affinity and selectivity for the human A1 AR, is a water-soluble small molecule, and has high oral bioavailability. In addition, this compound is an analog of an approved off-patent currently-marketed anti-asthma drug that is an A1 AR antagonist. Based on the completed IND-enabling GLP toxicology studies, ENDACEA expects that L-97-1 will be a safe drug with a high therapeutic index.
Following high dose oral administration, L-97-1 produced no seizure activity in a pro-convulsant animal model. It fits Lipinski’s rule of 5 for a successful orally active drug and is a Biopharmaceutics Classification System (BCS) Class 1 compound. Further, L-97-1 has a long shelf-life, can be stored at room temperature, and has a validated chemistry synthesis route with an expected low cost of goods at maturity.
© 2021 ENDACEA. All rights reserved. Website by web.com.